Abstract：OBJECTIVE: S100B protein, a special brain protein, is associated with the degree and prognosis of brain damage. This study determined the levels of S100B protein in cord blood and serum of neonates with asphyxia. The aim was to investigate the values of S100B protein in the diagnosis of neonatal asphyxia and in the identification of brain damage following neonatal asphyxia. METHODS: Thirty-two newborn infants with asphyxia (Asphyxia group) and 36 normal newborn infants (Control group ) were enrolled in this study. The cord blood and serum S100B protein was measured by ELISA on days 1, 3, and 7 after birth. RESULTS: Mean cord blood S100B protein levels in the Asphyxia group were significantly higher than those in the Control group ( P< 0.05 ). After birth, the serum S100B protein of infants with severe asphyxia complicated by brain damage increased progressively and was significantly higher than those infants with mild asphyxia on day 7 (P<0.01 ). On day 7 serum S100B protein content in infants who died was higher than in infants who survived, but there was no statistical differences . On day 3 asphyxiated infants with intracranial hemorrhage and/or hydrocephalus showed a higher level of serum S100B protein than those without brain damage (P<0.05). CONCLUSIONS: Serum S100B protein is a useful index for the diagnosis of neonatal asphyxia and the identification of brain damage following neonatal asphyxia.
WANG Qing-Hong,SONG Jian-Hui,WANG Xia et al. Clinical significance of serum S100B protein in brain damage following neonatal-asphyxia[J]. CJCP, 2005, 7(4): 318-320.
